ANTI-CANCER DRUGS

Scope & Guideline

Exploring New Horizons in Anti-Cancer Treatments

Introduction

Welcome to the ANTI-CANCER DRUGS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of ANTI-CANCER DRUGS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0959-4973
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationANTI-CANCER DRUG / Anti-Cancer Drugs
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal "ANTI-CANCER DRUGS" is dedicated to the dissemination of significant research findings in the field of oncology, particularly focusing on the development and evaluation of new therapeutic agents and strategies for cancer treatment. The journal emphasizes innovative approaches to drug development, efficacy, safety, and the biological mechanisms of action of anti-cancer therapies.
  1. Novel Drug Development:
    The journal covers research on new anti-cancer agents, including small molecules, biologics, and combination therapies, focusing on their mechanisms of action, pharmacodynamics, and pharmacokinetics.
  2. Clinical Trials and Case Reports:
    It publishes results from clinical trials, including phase I-III studies, as well as detailed case reports that highlight unique therapeutic responses or adverse events associated with anti-cancer drugs.
  3. Biomarkers and Personalized Medicine:
    The journal emphasizes the identification and validation of biomarkers that can predict treatment responses, guiding personalized therapy and improving patient outcomes.
  4. Mechanistic Studies:
    It includes studies that elucidate the molecular, cellular, and genetic mechanisms underlying cancer progression and drug resistance, contributing to a deeper understanding of cancer biology.
  5. Therapeutic Strategies and Combinations:
    The journal focuses on innovative therapeutic strategies, including combination therapies, immunotherapies, and targeted therapies, to overcome resistance and enhance treatment efficacy.
The journal "ANTI-CANCER DRUGS" reflects the dynamic nature of cancer research, with several emerging themes gaining prominence in recent publications. These trends indicate a shift towards more personalized and targeted approaches to cancer treatment.
  1. Immunotherapy and Checkpoint Inhibitors:
    There is a significant increase in studies examining the efficacy and safety of immunotherapies, including checkpoint inhibitors, indicating a trend towards harnessing the immune system in cancer treatment.
  2. Targeted Therapy Innovations:
    Emerging research on novel targeted therapies, particularly those addressing specific genetic mutations (e.g., EGFR, ALK), is on the rise, highlighting the importance of precision medicine in oncology.
  3. Combination Therapies:
    An increasing number of studies are exploring combination therapies that integrate traditional chemotherapy with targeted agents or immunotherapies, reflecting a trend towards multi-faceted treatment approaches.
  4. Research on Drug Resistance Mechanisms:
    There is a growing focus on understanding the mechanisms of drug resistance, particularly in relation to targeted therapies and immunotherapies, which is crucial for improving patient outcomes.
  5. Biomarker-Driven Treatment Approaches:
    The trend towards biomarker-driven treatment strategies is evident, with an emphasis on personalized medicine that tailors therapies based on individual patient profiles and tumor characteristics.

Declining or Waning

Despite the journal's comprehensive focus on the evolving landscape of cancer therapeutics, certain themes appear to be waning or receiving less emphasis in recent publications. These declining areas may reflect shifts in research priorities or emerging challenges in oncology.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in research focused solely on traditional chemotherapy agents without the integration of novel therapeutic strategies or combinations, as the field shifts towards targeted and personalized medicine.
  2. Monotherapy Studies:
    Publications centered around monotherapy approaches are becoming less frequent, with a growing emphasis on combination therapies that leverage synergies between different modalities to enhance efficacy.
  3. Exploratory Preclinical Studies:
    The journal has seen a reduction in the publication of exploratory preclinical studies that do not have a clear translational pathway to clinical application, as there is a stronger focus on studies that directly inform clinical practice.
  4. General Cancer Epidemiology:
    Research focused on broad epidemiological studies without a direct link to therapeutic interventions or drug efficacy is also waning, as the journal prioritizes studies with actionable insights for treatment.

Similar Journals

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Leading the Way in Medicinal Chemistry Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Drug Research

Catalyzing Collaboration in Drug Research
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Targeted Oncology

Transforming oncology with cutting-edge therapies.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

BRITISH JOURNAL OF PHARMACOLOGY

Elevating research standards in the field of pharmacology.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

ARCHIVES OF PHARMACAL RESEARCH

Connecting researchers to the forefront of pharmacological excellence.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.

MOLECULAR CANCER THERAPEUTICS

Connecting science and healing in the fight against cancer.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

INTERNATIONAL JOURNAL OF ONCOLOGY

Illuminating the path to effective cancer therapies.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

ONCOLOGY RESEARCH

Connecting Ideas, Advancing Oncology
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Anti-Cancer Agents in Medicinal Chemistry

Uncovering the future of anti-cancer strategies.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.